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Abstract
Background: Chinese herbal products (CHPs) have been frequently used among patients with chronic diseases
including hypertension; however, the co-prescription pattern of herbal formulae and single herbs remain uncharacterized.
Thus, this large-scale pharmacoepidemiological study evaluated the frequency and co-prescription pattern of CHPs for
treating hypertension in Taiwan from 2003 to 2009.
Methods: The database of traditional Chinese medicine (TCM) outpatient claims was obtained from the National Health
Insurance in Taiwan. Patients with hypertension during study period were defined according to diagnostic codes in the
International Classification of Disease Ninth Revision, Clinical Modification. The frequencies and percentages of herbal
formula and single herb prescriptions for hypertension were analyzed. We also applied association rules to evaluate the
CHPs co-prescription patterns.
Results: The hypertension cohort included 154,083 patients, 123,240 patients of which (approximately 80 %) had used
TCM at least once. In total, 81,582 visits involving CHP prescriptions were hypertension related; Tian-Ma-Gou-Teng-Yin and
Dan Shen (Radix Salvia Miltiorrhizae) were the most frequently prescribed herbal formula and single herb, respectively, for
treating hypertension.
Conclusions: This study elucidated the utilization pattern of CHPs for treating hypertension. Future studies on the efficacy
and safety of these CHPs and on drug–herb interactions are warranted.
Keywords: Complementary and alternative medicine, Traditional Chinese products, Hypertension, National Health
Insurance Research Database, Traditional Chinese medicine
Background
Hypertension, a major medical and public health concern
affecting approximately 972 million adults worldwide, is
the main risk factor for cardiovascular, brain, and kidney
diseases [1]. In addition, hypertension is consistently ac-
companied by other metabolic diseases, such as diabetes
mellitus and lipid abnormalities, the incidence of which
has increased recently [2, 3]. Moreover, hypertension
causes a loss of 92 million disability adjusted life years and
is responsible for 7.6 million excess deaths yearly [4].
Thus, antihypertensive drugs are primarily used to control
blood pressure, thereby preventing the occurrence or
progression of cardiovascular diseases and other com-
plications. Despite the prevalence of hypertension and
its associated complications, the control of this disease is
inadequate. Although several antihypertensive drugs, such
as diuretics, beta-blockers, calcium-channel blockers, and
angiotensin-converting enzyme or angiotensin II receptor
blockers, are available currently, a systolic/diastolic blood
pressure level of <140/90 mmHg, defined in the Seventh
Report of the Joint National Committee (JNC7) in 2003
and reaffirmed in the JNC8 in 2013, was achieved in no
more than 25 % of patients undergoing treatment for
hypertension worldwide [5]. Furthermore, the clinical
applications of antihypertensive drugs are limited by
numerous adverse side effects, such as dizziness, headache,
orthostatic hypotension, and decreased sexual function [6].
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Notably, complementary and alternative therapies have
become increasingly popular for treating hypertension [7],
particularly traditional Chinese medicine (TCM) [8],
because of their potential efficacy and few side effects [9,
10]. In addition to numerous published cases and random-
ized trials, an increasing number of experimental studies
have revealed multiple antihypertensive and protective
mechanisms of TCM [10]. In addition, various meta-
analyses and systemic reviews have recently evaluated the
effectiveness of TCM for hypertension [11].
TCM, including acupuncture, traumatology manipula-
tive therapies, and decoction, plays a crucial role in
health care in Taiwan and other Asian or Western coun-
tries. Chinese herbal products (CHPs), a modern form of
decoctions in which herbal formulae and single herbs
are concentrated into granulated compounds, are widely
prescribed by TCM physicians because of their conveni-
ence and quality. According to TCM theory, TCM physi-
cians evaluate patient conditions to prescribe one or
more herbal formulae combined with several single
herbs for each prescription. However, the CHPs used for
treating hypertension and their co-prescription patterns
remain not fully elucidated.
The National Health Insurance (NHI) program has
been reimbursing claims for CHPs, including single
herbs or herbal formulae, in Taiwan since 1995. By
using the National Health Insurance Research Database
(NHIRD), we analyzed the CHPs prescribed for treating
hypertension and their co-prescription patterns in
Taiwan. The results are a reference from which clinical
practitioners can understand the medicinal demands
and preferences of TCM users with hypertension and
thereby provide reliable information about CHP use.
Methods
Data source
The NHI program of Taiwan, executed in 1995, reim-
burses both Western medicines and CHPs. Approximately
99 % of Taiwan residents were included into the program
by the end of 2010 [12]. The electronic database of all
claims obtained from the NHIRD website involved
medical record files containing patient sex and date of
birth, date of medical visits, medical care facilities and
specialties, drugs, management and treatment, transferred
identification number, and three major diagnoses coded
according to the International Classification of Diseases,
Ninth Revision, Clinical Modification (ICD-9-CM) format.
The data regarding patient identity and institutions are
cryptographically scrambled to protect personal privacy.
Thus, the NHIRD offers an optimal platform for under-
standing the utilization pattern of CHPs prescribed by
licensed TCM physicians among the hypertension patient
population in Taiwan.
We analyzed a sample of one million randomly selected
patients from among the 22 million beneficiaries of the
NHI program in Taiwan, determining the prevalence of
prescribed CHPs in patients with hypertension from 2003
to 2009. This study adhered to strict confidentiality
guidelines according to regulations for personal elec-
tronic data protection and was approved by the Ethics
Review Board of Chang Gung Memorial Hospital,
Chia-Yi Branch (103-7691B).
Study subjects
The study cohort comprised patients diagnosed with
hypertension (ICD-9-CM codes: 401–405) three or more
times within one year from 2003 to 2009; information
was obtained from Western and TCM outpatient visit
records. All hypertension-related medical records were
analyzed during the study period. In the hypertension
cohort, patients who had at least one TCM outpatient
clinical visit from 2003 to 2009 were defined as TCM
users; among the TCM users, those who had used CHPs
were defined as CHP users, whereas those with no TCM
outpatient records were defined as non-TCM users. In
addition, we obtained the prescription files containing
the CHP prescription records corresponding to patient
outpatient visits that involved a hypertension diagnosis
to assess the corresponding CHP co-prescriptions for
hypertension.
Study variables
Patient demographic characteristics were investigated to
determine the main independent variables affecting
TCM use in the hypertension cohort. In addition to
patient sex, patient age was categorized into three
groups: <45, 45–65, >65 years. The monthly insurance
salaries of patients were grouped into four levels: NT$0,
NT$1–NT$15,840, NT$15,841–NT$25,000, >NT$25,000.
Urban levels in this study were divided into four strata
according to the location of NHI registration. Level 1
referred to the most urbanization and level 4 indicated the
least urbanization. We also included the following clinical,
potential comorbidities related to hypertension from the
NHIRD as independent variables: ischemic heart disease
(ICD-9-CM codes: 410–414), cardiovascular disease (ICD-
9-CM codes: 430–438), atherosclerosis (ICD-9-CM code:
440), hyperlipidemia (ICD-9-CM code: 272), and type II
diabetes mellitus (ICD-9-CM code: 250).
Traditional Chinese medicine
TCM, comprising CHPs, acupuncture, and traumatology
manipulative therapies, has developed over the past
millennia and is most widely adopted by patients in
Taiwan. Prescriptions by TCM physicians based on the pa-
tients’ varying signs and symptoms may comprise one or
more herbs (formulae). Chinese herbal drugs or formulae
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are manufactured as powder or fine granules that can be
easily mixed in a single prescription. Information regard-
ing reimbursed CHPs, including the name of each CHP,
the proportion of each constituent, the date and period of
drug approval, the code, and the manufacturer name, were
obtained from the Department of Chinese Medicine and
Pharmacy website.
Statistical analysis
Drug registration numbers from the Department of
Chinese Medicine and Pharmacy website were linked to
the outpatients visit records of the hypertension cohort.
Database software, SAS Version 9.2 (SAS Institute Inc.,
Cary, NC, USA), was used for data linkage and descriptive
statistic analysis of drug utilization pattern, including fre-
quencies, percentages, average daily dose(g), and average
use duration(days) of herbal formulae or single herbs for
treating hypertension. In general, TCM physicians prescribe
one or more herbal formulae including several single herbs
to treat patients. In this study, the association rules of data
mining were applied to assess the co-prescriptions of CHPs
for hypertension. The support factor was the proportion of
the co-prescriptions of medications A and B among all pre-
scriptions, and the confidence factor was the proportion of
the co-prescriptions of medications A and B among all pre-
scriptions containing medication A (Fig. 1). We used 0.5 %
as the minimum support factor and 30 % as the minimum
confidence factor [13].
Results
In this study, we identified 154,083 patients who had visited
the outpatient department for hypertension three or more
times within one year during the study period among the
study cohort of one million randomly sampled patients.
Table 1 shows a summary of the patient characteristics. Of
these patients, 123,240 patients (approximately 80 %) used
TCM at least once, and 116,070 patients used CHPs.
Female patients used TCM more frequently than did
male patients. The peak age of the patients receiving
TCM treatment ranged between 45 to 65 years (47.4 %).
In addition, patients with comorbidities such as metabolic
diseases, including diabetes mellitus or hyperlipidemia,
were more likely to consider TCM treatment.
A B
Fig. 1 Basic Concepts and Algorithms of Association rules
Table 1 Characteristics of Hypertension population from one
million random sampling cohort of the NHIR database
Characteristics Non-TCM
Users
TCM users CHP users
No. % No. % No. %
Age
<45 3802 12.3 18768 15.2 17653 15.2
45-65 12790 41.5 58453 47.4 55219 47.6
>65 14251 46.2 46019 37.3 43198 37.2
Gender
Female 11509 37.3 64826 52.6 61594 53.1
Male 19334 62.7 58414 47.4 54476 46.9
Insurance salaries(NTD$/
month)1
0 5965 19.3 21891 17.8 20485 17.7
1-15840 5653 18.3 18185 14.8 16980 14.6
15841-25000 12882 41.8 57967 47.0 55006 47.4
>25000 6343 20.6 25197 20.4 23599 20.3
Urban Level2
1 9069 29.4 35622 28.9 33226 28.6
2 13023 42.2 55239 44.8 52063 44.9
3 5538 18.0 20546 16.7 19486 16.8





9607 31.1 41603 33.8 39237 33.8
Cardiovascular disease
(430–438)
7466 24.2 27218 22.1 25592 22.1
Atherosclerosis(440) 931 3.0 3814 3.1 3616 3.1
Hyperlipidemia (272) 11476 37.2 52627 42.7 49629 42.8
Type II Diabetes Mellitus(250) 9773 31.7 39936 32.4 37514 32.3
Total 30843 123240 116070
1. NTD, New Taiwan dollar 1USD≒30NTD
2. 1:most urbanization; 4:least urbanization
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Table 2 presents the estimated prevalence of hyperten-
sion (15.4 %) in Taiwan from 2003 to 2009, indicating that
the prevalence increased with an increase in age for both
sexes. The prevalence of hypertension was 2.5 %, 32.7 %,
and 67.6 % in women and 4.1 %, 32.6 %, and 60.8 % in
men aged <45, 45–65, and > 65 years, respectively.
Between 2003 and 2009 in Taiwan, 81,582 hypertension-
related outpatient visits involved CHP prescriptions by
TCM physicians. Table 3 presents the most frequently
prescribed herbal formulae and single herbs during these
outpatient visits and includes data on the frequency of
prescriptions, average daily doses, and average prescrip-
tion durations. The most commonly prescribed herbal
formula for hypertension was Tian-Ma-Gou-Teng-Yin
(27.5 %), followed by Gou-Teng-San (12.5 %), Xue-Fu-
Zhu-Yu-Tang (9.2 %), Jia-Wei-Xiao-Yao-San (7.8 %),
and Zhi-Bo-Di-Huang-Wan (6.1 %). Moreover, Dan
Shen (Radix Salvia Miltiorrhizae) (17.1 %) was the
most commonly prescribed single herb for patients
with hypertension, followed by Gou Teng (Ramulus
Uncariae cum Uncis) (10.4 %), Ge Gen (Radix Puerariae)
(8.4 %), and Niu Xi (Radix Achyranthis Bidentatae) (6.4 %).
According to the association rules in Table 4, the most
commonly prescribed combination of two herbal formu-
lae for hypertension was Tian-Ma-Gou-Teng-Yin and
Xue-Fu-Zhu-Yu-Tang (support factor, 2.64 %). The most
commonly prescribed combination of a herbal formula
and a single herb for treating hypertension was Tian-
Ma-Gou-Teng-Yin and Dan Shen (support factor,
5.11 %). In addition, TCM physicians frequently pre-
scribed Tian-Ma-Gou-Teng-Yin in combination with
other herbal formulae, such as Xue-Fu-Zhu-Yu-Tang,
Zhi-Bo-Di-Huang-Wan, Qi-Ju-Di-Huang-Wan, and Long-
Dan-Xie-Gan-Tang, or with another single herb, such
as Dan Shen, Ge Gen, and Xia Ku Cao (Spica Prunel-
lae Vulgaris). The most commonly prescribed combin-
ation of two single herbs was Tian Ma (Rhizoma
Gastrodiae Elatae) and Gou Teng (support factor,
2.28 %). Moreover, physicians frequently prescribed
Dan Shen in combination with other single herbs,
such as Ge Gen, Chuan Qi (Radix Notoginseng), Gou
Teng, and Shan Zha (Crataegi Fructus) for treating
hypertension.
Discussion
To the best of our knowledge, this is the first large, ran-
dom national-level study to document the frequency and
co-prescription pattern of CHPs, including herbal for-
mulae and single herbs, for hypertension. The results
were obtained by analyzing the computerized insurance
reimbursements in Taiwan. The term “hypertension” did
not exist in ancient China; thus, TCM has been used to
treat hypertension-related symptoms in clinical practice
rather than to decrease blood pressure values. In other
words, TCM physicians treat patients according to a
holistic consideration of the body’s condition. The most
common clinical manifestations of hypertension in-
clude dizziness, headache, fatigue, shortness of breath,
lassitude in the loins and knees, memory loss, dry eyes,
Table 2 Patient number and estimated prevalence of
hypertension in Taiwan from one million random sampling
cohort of the NHIR database 2003-2009
Age/gender All Female Male
All 154083 15.4 % 76335 15.1 % 77748 15.7 %
<45 22570 3.3 % 8561 2.5 % 14009 4.1 %
45-65 71243 32.6 % 36066 32.7 % 35177 32.6 %
>65 60270 64.2 % 31708 67.6 % 28562 60.8 %
Table 3 Top ten herbal formulae and single herb prescribed by











Tian-Ma-Gou-Teng-Yin 22,403 27.5 % 9.7 10.4
Gou-Teng-San 10,211 12.5 % 7.6 9.2
Xue-Fu- Zhu-Yu-Tang 7,540 9.2 % 7.7 10.7
Jia-Wei-Xiao-Yao-San 6,342 7.8 % 7.1 11.4
Zhi-Bo-Di-Huang-Wan 4,999 6.1 % 6.4 11.6
Qi-Ju-Di-Huang-Wan 4,828 5.9 % 4.9 12.7
Long-Dan-Xie-Gan-Tang 4,589 5.6 % 8.4 10.2
Liu-Wei-Di-Huang-Wan 4,058 5.0 % 6.8 11.0
Zhi-Gan-Cao-Tang 3,834 4.7 % 8.0 11.5
Shu-Jing-Huo-Xue-Tang 3,661 4.5 % 5.2 11.8
Single Herb
Dan Shen (Radix Salvia
Miltiorrhizae)
13,970 17.1 % 2.3 11.3
Gou Teng (Ramulus
Uncariae cum Uncis)
8,492 10.4 % 2.0 10.4
Ge Gen (Radix Puerariae) 6,846 8.4 % 1.9 10.4
Niu Xi (Radix Achyranthis
Bidentatae)
5,230 6.4 % 2.3 11.9
Xia Ku Cao (Spica
Prunellae Vulgaris)
4,964 6.1 % 2.2 10.8
Da Huang (Radix et
Rhizoma Rhei)
4,964 6.1 % 1.0 10.8
Du Zhong (Cortex
Eucommiae)
4,576 5.6 % 1.7 11.9
Tian Ma (Rhizoma
Gastrodiae Elatae)
4,284 5.3 % 1.7 10.9
Chuan Qi (Radix
Notoginseng)
4,189 5.1 % 3.0 10.5
Shan Zha (Crataegi
Fructus)
4,173 5.1 % 1.8 10.8
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and palpitations [14]. TCM physicians prescribe various
Chinese herbal formulae or single herbs to treat such
patients by differentiating the syndromes according to
the signs and symptoms caused by hypertension and
TCM principles.
Because of the unsatisfactory efficacy and potential
side effects of antihypertensive drugs, including dizzi-
ness, headache, orthostatic hypotension, and decreased
sexual function after long term use [6],the use of TCM
as an alternative therapeutic option for hypertension has
been increasing in Taiwan. Although several studies on
CHPs have reported their effectiveness in treating hyper-
tension [7, 8, 15], additional studies are warranted to
further investigate the safety and efficacy of CHPs and
their drug interactions.
Tian-Ma-Gou-Teng-Yin, the most commonly pre-
scribed herbal formula for hypertension in Taiwan, as re-
ported by a previous study [16], has been demonstrated
to lower blood pressure and total cholesterol, prevent
the incidence of stroke in patients with hypertension,
and improve clinical symptoms and quality of life [17,
18]. Several clinical studies and animal experiments have
revealed that Tian-Ma-Gou-Teng-Yin decreases endothelin,
angiotensin II [19], superoxide dismutase [20],and calcium
gene-related peptides [21], regulates the secretions and
serum concentrations of vasoactive substances [22],
and enhances insulin resistance [23]. However, a review
article reported that no randomized, controlled clinical
trials have compared the effects of Tian-Ma-Gou-Teng-
Yin with those of a placebo or no treatment. Thus, fur-
ther research is warranted to establish the efficacy of
Tian-Ma-Gou-Teng-Yin [24].
Gou-Teng-San is the second most commonly prescribed
herbal formula for hypertension. Gou-Teng-San is often
prescribed for headache and vertigo and has recently been
prescribed for treating hypertension and dementia [25].
Reportedly, the antihypertensive effect of Gou-Teng-San is
mediated by calcium channel antagonist action, which was
demonstrated clearly in the pharmacological analysis of
hirsutine, an indole alkaloid isolated from Gou Teng [26].
The other possible mechanism for the antihypertensive
effect of Gou-Teng-San is the radical scavenging activity
of Gou Teng, a main component herb of Gou-Teng-San,
in the isolated aorta with the endothelium, reported in an
experimental animal model [27].
Xue-Fu-Zhu-Yu-Tang, the third most commonly pre-
scribed herbal formula for hypertension, is commonly
prescribed for cardiovascular diseases by TCM physi-
cians in clinical practice. Patients with hypertension
typically exhibit enhanced platelet adhesion, aggrega-
tion, releasing reaction, and dysfunction in erythrocyte
deformability; hence, improving erythrocyte deformability
and inhibiting platelet activation might be helpful in treat-
ing patients with hypertension. The use of CHPs might
improve blood rheological conditions, including coagula-
tion, viscosity, blood flow, and deformability [10]. Certain
experimental studies have demonstrated that Xue-Fu-
Zhu-Yu-Tang can increase coronary blood flow, improve
cardiac microcirculation, prevent platelet aggregation, and
accommodate blood lipids [28, 29].
Although Jia-Wei-Xiao-Yao-San is rarely prescribed
alone by TCM physicians for treating hypertension,
this study revealed that it was the fourth most com-
monly prescribed herbal formula for hypertension.
Table 4 Co-prescriptions (one to one association) of single herbs and herbal formulae for Hypertension population
Herbal associations Support (%) Confidence (%) Transaction
count
Association rule
Single herb to single herb 2.28 43.46 1862 Tian Ma (Rhizoma Gastrodiae Elatae)→ Gou Teng (Ramulus
Uncariae cum Uncis)
2.19 26.09 1785 Ge Gen (Radix Puerariae)→Dan Shen (Radix Salvia Miltiorrhizae)
2.16 42.15 1764 Chuan Qi (Radix Notoginseng)→Dan Shen (Radix Salvia Miltiorrhizae)
2.14 20.56 1745 Gou Teng (Ramulus Uncariae cum Uncis)→Dan Shen (Radix Salvia
Miltiorrhizae)
1.69 33.09 1380 Shan Zha (Crataegi Fructus)→ Dan Shen (Radix Salvia Miltiorrhizae)
Herbal formula to herbal
formula
2.64 28.55 2151 Xue-Fu- Zhu-Yu-Tang→ Tian-Ma-Gou-Teng-Yin
1.89 30.77 1538 Zhi-Bo-Di-Huang-Wan→ Tian-Ma-Gou-Teng-Yin
1.82 30.91 1486 Qi-Ju-Di-Huang-Wan→ Tian-Ma-Gou-Teng-Yin
1.60 28.49 1307 Long-Dan-Xie-Gan-Tang→ Tian-Ma-Gou-Teng-Yin
Herbal formula to single
herb
5.11 18.61 4166 Tian-Ma-Gou-Teng-Yin→Dan Shen (Radix Salvia Miltiorrhizae)
2.66 9.68 2168 Tian-Ma-Gou-Teng-Yin→ Ge Gen (Radix Puerariae)
2.47 9.00 2014 Tian-Ma-Gou-Teng-Yin→ Xia Ku Cao (Spica Prunellae Vulgaris)
2.02 21.83 1645 Xue-Fu- Zhu-Yu-Tang→ Dan Shen (Radix Salvia Miltiorrhizae)
1.64 5.99 1340 Tian-Ma-Gou-Teng-Yin→Du Zhong (Cortex Eucommiae)
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TCM physicians combined it with another herbal formula
and/or single herb according to patient symptoms
[30]. Moreover, previous studies have reported that
Jia-Wei-Xiao-Yao-San is the most commonly used
CHP for relieving menopausal symptoms, such as
hot flushes, and other related symptoms, including
emotional disturbances and insomnia [31, 32]. Pa-
tients with such symptoms might be at a higher risk
of developing hypertension, and this may explain the
frequent prescription of Jia-Wei-Xiao-Yao-San for
hypertension.
As observed in Table 3, Dan Shen, the dried root and
the rhizome of Salviamiltiorrhiza Bge (Labiatae), is the
most frequently prescribed single herb for hypertension.
Studies have reported the multiple pharmacological
activities of Dan Shen in the cardiovascular system, in-
cluding anti-hypertension [33], anti-thrombosis [34],
anti-atherosclerosis [35],and cardioprotection [36], in
addition to improved microcirculation in the brain
and heart [37]. Previous studies have demonstrated
that the active chemical constituents of Dan Shen,
particularly, tanshinone IIA, danshensu, salvianolic
acid B, lithospermicacids, and cryptotanshinone, ex-
hibit beneficial effects in managing cardiovascular dis-
eases [38, 39]. For over five decades, using Dan Shen
products has been considered extremely safe, with no
reports of any major adverse effect [40]. Although
studies have reported its interactions with warfarin,
salicylate, diazepam, and ginseng [41–44], no studies
have reported interactions between antihypertensive
drugs and Dan Shen.
Gou Teng is the second most frequently prescribed
single herb for hypertension. Certain studies have reported
that alkaloids are the main active pharmacological compo-
nents of Gou Teng. Of these components, rhynchophyl-
line and isorhynchophylline are the chief ingredients,
which play a major role as hypotensive agents [45]. As
observed in Table 4, TCM physicians often used Tian Ma
in combination with Gou Teng for treating hypertension
or hypertension-related symptoms. Tian Ma is also a cru-
cial Chinese herb used for decreasing blood pressure
values. Moreover, recent studies have demonstrated that it
can promote a stable decrease in blood pressure, improve
clinical symptoms, regulate the rennin–angiotensin sys-
tem, improve insulin resistance and salt sensitivity, and
decrease serum levels of total cholesterol, triglycerides,
and low-density lipoprotein cholesterol [15, 46, 47].
To increase treatment efficacy and compensate for
insufficiency of another single herb, TCM physicians
often use two single herbs as a herb pair. Tian Ma used
with Gou Teng is an example of a herb pair that in-
creases treatment efficacy and exerts similar effects in
the cardiovascular and central nervous systems. This
might explain why Tian Ma and Gou Teng are the two
most frequently prescribed single herbs in combination
for treating hypertension.
In addition, TCM physicians often used Ge Gen to
treat hypertension-related symptoms such as headache
and dizziness. Previous studies have reported that Ge
Gen primarily comprises isoflavonoids, such as puerarin,
diadzein, and daidzin, which exhibit anti-hypertensive
[48] and antithrombotic effects [49] and reduce plasma
cholesterol levels [50].
TCM physicians treat patients with hypertension ac-
cording to syndrome differentiation theory, and pre-
scriptions differed among TCM physicians because of
their experience and knowledge. In the present study,
the co-prescription patterns of CHPs by TCM physi-
cians differed from that of decoctions. TCM physicians
prescribed a thoroughly recorded formula as the core
formula and subtracted or added herbs in a decoction
preparation to fit a patient’s condition according to
TCM theory. When they prescribed CHPs, which are
extracted and completely mixed together in the manu-
facturing process, TCM physicians only added single or
multiple herbs into the core formula, but subtracted or
changed the proportions of herbs in the finished herbal
products. Thus, TCM physicians combined other for-
mulae or herbs in each prescription to treat patients.
Moreover, the NHI in Taiwan only reimburses CHPs
and not decoctions, eliciting our concern that the co-
prescription pattern of CHPs with a high support factor
might indicate a typical practice pattern among TCM
physicians in Taiwan [51]. Although 5.9 CHPs were
prescribed on average during one hypertension-related
TCM outpatient visit in the present study, the co-
prescription of three or more Chinese herbal formulae
or single herbs for hypertension had a low support factor;
thus, we determined two co-prescription patterns (one to
one association) in the study.
Tian-Ma-Gou-Teng-Yin and Xue-Fu-Zhu-Yu-Tang was
the most commonly prescribed combination of two herbal
formulae for treating hypertension, whereas Tian-Ma-
Gou-Teng-Yin and Dan Shen were the most frequently
prescribed combination of an herbal formula and a single
herb for treating hypertension. In addition, Tian-Ma-Gou-
Teng-Yin and Dan Shen were the most frequently co-
prescribed herbal formula and single herb for treating
hypertension. Furthermore, we could investigate the
most common corresponding diagnoses or syndromes
related to hypertension. As in a previous study [32], we
can conduct clinical trials on the efficacy and safety of
these co-prescribed CHPs according to the results of
our study in the future.
Although patients with hypertension primarily seek
conventional therapy, TCM is crucial in complementary
and alternative medicines. In other words, most patients
with hypertension who went to TCM outpatient clinical
Yang et al. BMC Complementary and Alternative Medicine  (2015) 15:163 Page 6 of 8
practices for treatment often had an initial hypertension
diagnosis from Western medicine practitioners. Further-
more, modern TCM physicians are trained in Western
medicine knowledge during undergraduate or refresher
courses. Although, the therapeutic principles of TCM
are based on the results of syndrome differentiation,
which differs from the principles of Western medicine,
TCM physicians in Taiwan must use ICD-9-CM codes
in the NHI claims database to diagnose diseases during
outpatient visits.
A previous study revealed that some patients seek
TCM treatment for problems other than hypertension,
whereas some patients were treated for hypertension
with acupuncture and traumatology manipulative therapies
[16]. This might explain why only 81,582 outpatient
hypertension-related visits involved CHP prescriptions
by TCM physicians among the 123,240 TCM visits in-
vestigated in the present study. The prevalence of
hypertension increases with age, especially when people
are older than 65 years. These findings were consistent
with those of a previous study [52]. However, our co-
hort included patients who had visited the outpatient
department because of hypertension three or more
times within one year alone during the study period of
2003–2009; this might have led to an underestimation
of the prevalence of hypertension in Taiwan. In the
present study cohort, women and patients aged 45–65
years used TCM more frequently than did men and pa-
tients in the other age groups. In addition, the patients
with hypertension who experienced additional comor-
bidities such as metabolic diseases were more likely to
consider TCM treatments.
This study had three limitations. First, we could not
obtain definitive conclusions regarding the relationship
between the severity of hypertension and TCM utilization.
Second, apparently, TCM physicians in Taiwan use
ICD-9-CM for diagnosis in clinical practice, but no reli-
able and suitable disease coding system exists for TCM.
Several variations were observed in the prescription
patterns for treating hypertension because the therapeutic
principles of TCM are based on the results of syndrome
differentiation. Thus, developing a coding system for
TCM diagnostic classifications in the future is critical and
will assist TCM research greatly. Third, NHI provided re-
imbursements for only finished herbal products prescribed
by TCM physicians and did not include decoctions and
CHPs provided by pharmacies; this might have led to the
underestimation of the frequency of TCM utilization.
However, this underestimation might be small because
most CHPs were reimbursed.
Conclusions
This study analyzed a cohort of one million randomly
sampled patients from the NHIRD from 2003 to 2009
and documented the frequency and co-prescription pat-
tern of CHPs for hypertension in clinical practice in
Taiwan. However, further research must be conducted to
strengthen the available clinical evidence regarding the
efficacy and safety of CHPs in improving hypertension-
related mortality and morbidity as well as the drug–herb
interactions.
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